Pharmafile Logo

long-term condition

- PMLiVE

Scale & Strategy: Essential tools for transforming the commercial model

Most life sciences companies know they need to move their multichannel marketing forward, but that requires managing a greater volume of tactics that need to be developed, approved, implemented, and...

EU flag

Italian pharma scandals prompts call for EU-wide pricing probe

Aspen fined €5.2m for threat to halt supply of cancer drugs if price hikes not accepted

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

- PMLiVE

Clinical trials enter the genomic age

Looking at the factors driving this change and assessing the benefits

- PMLiVE

Dr Andrew Webber joins Life Healthcare Communications

He becomes a medical director at the agency

- PMLiVE

NHS marks its Twitter debut with story-sharing initiative

Three-month project will see a patient or staff member take over the new account

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

- PMLiVE

EpiDemic

Getting serious about drug pricing

Astellas bolsters oncology clinical development leadership

Dr Steven Benner joins while Dr Anne Keating is promoted

- PMLiVE

Immuno-oncology’s evolution: implications for pharma market researche

Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached...

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links